A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
Ronan Joseph Kelly, Anish Thomas, Arun Rajan et al. · Annals of Oncology · 2013
Cited by 166 works. doi:10.1093/annonc/mdt249 Open-access PDF
Authors
- Ronan Joseph Kelly
- Anish Thomas
- Arun Rajan
- Guinevere Chun
- Ariel López-Chávez
- Éva Szabó
- Shawn D. Spencer
- C.A. Carter
- Udayan Guha
- Sean Khozin
- Srinivasu Poondru
- C. Van Sant
- Anne Therese Keating
- Seth M. Steinberg
- William Douglas Figg
- Giuseppe Giaccone
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- The Hallmarks of Cancer
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
- A Sequencing Method Based on Real-Time Pyrophosphate
- Control of apoptosis and mitotic spindle checkpoint by survivin
- Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer.
- Validating survivin as a cancer therapeutic target
- Pharmacokinetic/pharmacodynamic data analysis : concepts and applications